 buy addit detail head
 data readout mileston pt
messag report result updat phase fight trial
evalu bemarituzumab bema data readout compani paus
enrol phase fight enrol pend futil analysi
also guid initi efficaci data patient receiv singl agent
esmo see planner note along initi safeti data patient
receiv fpa keytruda pipelin out-licens program remain
track reduc pt due increas uncertainti potenti
bema delay head fight futil analysi enrol paus off-set higher
phase fight trial track hit enrol constitut
futil analysi recal ad futil analysi greater-
than-expect enrol patient vs expect test posit
see earn note compani expect paus enrol pend
potenti success futil analysi aim earli efficaci signal
higher hurdl typic futil analysi aim confirm experiment arm
harm
antibodi develop progress nice head monotherapi
efficaci readout esmo see esmo planner note guid present singl
agent efficaci patient breast ovarian endometri cancer though caveat
hand patient would radiograph scan well safeti
data first patient receiv combin keytruda
compani mention near complet safeti lead-in keytruda
expect open ovarian cancer expans cohort later month hope
achiev respons rate least doubl observ monotherapi
orr link orr nivolumab head go/
track read initi dose escal safeti data
anticip earli efficaci readout similar
readout link given rel shorter time trial initi data
readout compani continu dose escal cohort current enrol
increment updat across out-licens program phase ii trial antibodi
cabiralizumab combin nivolumab complet enrol immin
accord enabl read data toward go-phas
decis pancreat cancer antibodi cite
increas phase trial size patient current includ
either program estim
updat estim account result maintain buy pt
end quarter cash invest reduc pt
previous modestli adjust probability-of-success assumpt downward
phase fight trial given slight increas uncertainti head futil
analysi off-set increas elig patient popul
also modestli push launch year assumpt bemarituzumab given
expect enrol paus confid bemarituzumab success
slightli diminish earli clinic pipelin out-licens program repres potenti
upsid current valuat stock trade near cash level continu
find risk/reward own favor remain buy rate
page analyst certif import disclosur
valuat risk
valu per share previous use dcf base valuat valuat
includ lead product bemarituzumab well probability-adjust cash flow deriv
compani pipelin use discount rate consist commerci stage
biotech compani coverag termin growth rate appli termin
risk includ regulatori commerci setback potenti emerg new competitor
/or lower product sale expect risk intellectu properti risk manag
page analyst certif import disclosur
total cost expens
interest incom net
incom tax
guggenheim secur llc estim sec file
page analyst certif import disclosur
